CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2B, above the global median of $1.18B
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.00BUSDvs all stocks (USD)
Revenue (TTM)
188.73MUSDvs all stocks (USD)
Profit Margin
-51.73%vs Biotechnology peers
Beta
1.58xvs all stocks
52-Week Change
113.63%vs all stocks
Market Capitalization
2.00BUSDvs all stocks (USD)
Enterprise Value
2.11BUSDvs all stocks (USD)
Forward P/E
14.61xvs Biotechnology peers
Price to Sales (TTM)
10.57xvs Biotechnology peers
Enterprise to Revenue
11.18xvs Biotechnology peers
Enterprise to EBITDA
-31.79xvs Biotechnology peers
Gross Margin
90.93%vs Biotechnology peers
Profit Margin
-51.73%vs Biotechnology peers
Operating Margin
0.15%vs Biotechnology peers
Return on Assets (TTM)
-18.06%vs Biotechnology peers
Revenue (TTM)
188.73MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.81USDUpdated Sep 28, 2026Quarterly Revenue Growth
199.20%vs Biotechnology peers
Gross Profit (TTM)
171.46MUSDvs all stocks (USD)
EBITDA (TTM)
-66.34MUSDvs all stocks (USD)
Net Income (TTM)
-97.64MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
199.22%vs Biotechnology peers
Operating Cash Flow (TTM)
-158.92MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-106.98MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
109.79MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
12.45MUSDFY2025 · Dec 31, 2025Gross Profit
97.34MUSDFY2025 · Dec 31, 2025Operating Income
-124.86MUSDvs all stocks (USD)
Pre-tax Income
-153.42MUSDFY2025 · Dec 31, 2025Income Tax Expense
78.00KUSDFY2025 · Dec 31, 2025Net Income
-153.49MUSDFY2025 · Dec 31, 2025EBIT
-138.07MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-135.66MUSDFY2025 · Dec 31, 2025Research & Development
67.11MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
155.10MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.96MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
15.35MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.19USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.19USDFY2025 · Dec 31, 2025Basic Shares Outstanding
48.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
48.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-153.49MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-160.55MUSDFY2025 · Dec 31, 2025Free Cash Flow
-160.84MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.41M of depreciation against 289K of capital expenditure, and its own free-cash-flow line reads -162.73M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
112.09MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-153.49MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.41MUSDFY2025 · Dec 31, 2025Stock-based Compensation
11.96MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.60MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-12.78MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
286.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.54MUSDFY2025 · Dec 31, 2025Capital Expenditures
-289.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-77.40MUSDFY2025 · Dec 31, 2025Sale of Investments
139.25MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
61.56MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.85MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
37.95MUSDFY2025 · Dec 31, 2025Shares Outstanding
48.87MSharesUpdated Sep 28, 2026Float Shares
43.41MSharesUpdated Sep 28, 2026Shares Short
6.25MSharesUpdated Sep 28, 2026Short Ratio
7.62daysvs all stocks
Short % of Shares Outstanding
13.04%vs all stocks
% Held by Insiders
3.49%vs all stocks
% Held by Institutions
100.45%vs all stocks
Total Cash (MRQ)
107.97MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.21USDUpdated Sep 28, 2026Total Debt (MRQ)
196.13MUSDvs all stocks (USD)
Current Ratio (MRQ)
3.80xvs Biotechnology peers
Book Value per Share (MRQ)
-2.71USDUpdated Sep 28, 2026Total Assets
200.46MUSDvs all stocks (USD)
Total Current Assets
186.02MUSDFY2025 · Dec 31, 2025Total Liabilities
305.93MUSDFY2025 · Dec 31, 2025Total Non-current Assets
14.43MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
259.51MUSDFY2025 · Dec 31, 2025Total Current Liabilities
46.42MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
110.75MUSDFY2025 · Dec 31, 2025Other Short-term Investments
9.71MUSDFY2025 · Dec 31, 2025Accounts Receivable
33.08MUSDFY2025 · Dec 31, 2025Inventory
16.46MUSDFY2025 · Dec 31, 2025Accounts Payable
12.14MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.18MUSDFY2025 · Dec 31, 2025Long-term Debt
128.33MUSDFY2025 · Dec 31, 2025Common Stock (Book)
133.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-959.72MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-105.47MUSDvs all stocks (USD)
52-Week Low
15.86USDUpdated Sep 28, 202652-Week High
50.81USDUpdated Sep 28, 202652-Week Change
113.63%vs all stocks
Beta
1.58xvs all stocks
50-Day MA
43.94USDUpdated Sep 28, 2026200-Day MA
29.46USDUpdated Sep 28, 2026Avg 10-Day Volume
686.24KSharesUpdated Sep 28, 2026Avg 30-Day Volume
784.58KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.97USDUpdated Sep 28, 2026Other Income / Expense
-670.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.91Profit Margin: -0.52
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2B, above the global median of $1.18BNotable
Market cap (USD): 2,001,659,095Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Mesoblast Limited
Tier 1ProductionApproval-Gated PipelineRule
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nuvation Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sarepta Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Travere Therapeutics Inc.
2 interpretationsRevenue Growing With Receivables GrowingHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Iovance Biotherapeutics, Inc.
2 interpretationsRevenue Growing With Receivables GrowingHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Mirum Pharmaceuticals Inc.
2 interpretationsRevenue Growing With Receivables GrowingHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC